儿科患者群体中的β-基酸盐升高及其相关病理:一系列回顾性病例
Nasim Haghandish1, Anthea Girdwood2,3, Christopher Milroy1,4,5
1Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada.
Journal of forensic sciences
|November 17, 2025
概括
儿童的β-基酸盐 (BHB) 水平升高表明他们患有酸性. 这项研究分析了儿科死亡的死后BHB值和组织学,在各种致命疾病和相关组织变化中发现了BHB.
科学领域:
- 法医病理学 法医病理学
- 儿科病理学 儿科病理学
- 毒理学 毒理学 毒理学
背景情况:
- 升高的β-基酸盐 (BHB) 是酸性的关键指标.
- 有限的数据存在于死后BHB值和相关的发现在儿科致命酸性脂肪酸.
- 了解这些标志物对于准确诊断儿科死亡至关重要.
研究的目的:
- 为了调查儿科死亡的死后β-基酸盐 (BHB) 水平.
- 为了将BHB水平与儿童的临床和组织学发现相关联.
- 确定BHB在诊断儿科病例中致命酸性脂肪酸症的实用性.
主要方法:
- 儿科尸检记录的回顾性案例系列 (2010-2022年).
- 对儿童 (18岁以下) 玻璃体BHB (>2 mmol/L) 或血液BHB (>200 mg/L) 升高的分析.
- 心脏,肺,肝脏和脏的组织学检查,并对发现进行评分.
主要成果:
- 20例 (3.9%) 符合纳入标准,年龄从死胎到17岁不等.
- 平均玻璃体BHB为3.9毫摩尔/升;平均血液BHB为416毫克/升.
- 组织学变化包括肝硬化,管真空和心脏真空;玻璃体BHB与管真空相关 (p=0.014).
- 在糖尿病酸性症,感染,恶性瘤,创伤,先天性心脏病和药物毒性病例中发现了升高的BHB.
结论:
- 死亡后BHB水平升高存在于各种致命的儿科疾病中,不仅限于糖尿病酸性脂肪酸.
- 肝脏和脏等器官的组织学变化与儿童BHB升高有关.
- 死后BHB分析对于诊断致命的酸性脂肪酸和了解其对儿科死亡的影响是有价值的.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
182
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
182
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
234
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
234
Inborn Errors of Metabolism
688
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
688
Pedigree Analysis
88.7K
Overview
88.7K
Pharmacokinetics in Pediatric Patients: Drug Distribution
249
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
249
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K


